A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors

Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Histologically or cytologically documented, locally advanced or metastatic solid tumors for which standard therapy either does not exist or has proven ineffective or intolerable * Evaluable disease or disease measurable * Life expectancy \> or = 12 weeks * Adequate hematologic and end organ function * For female patients of childbearing potential and male patients with partners of childbearing potential, use of an effective form of contraception with continued use for study duration and up to 3 months or more following discontinuation of treatment drug * Fluorodeoxyglucose positron emission tomography (FDG-PET) avid disease on baseline scan For enrollment in part 2, patients must meet all of the following: * Measurable disease * No more than four prior systemic therapies for locally advanced or metastatic cancer Exclusion Criteria: * History of prior significant toxicity from another MEK inhibitor or ERK inhibitor requiring discontinuation of treatment * Evidence of visible retinal pathology as assessed by ophthalmologic examination that is considered a risk factor for retinal vein thrombosis * History of glaucoma * Intraocular pressure \> 21 mmHg as measured by tonometry * Predisposing factors to retinal vein occlusion (RVO) * History of RVO, neurosensory retinal detachment, or neovascular macular degeneration * Allergy or hypersensitivity to components of the cobimetinib or GDC-0994 formulation * Palliative radiotherapy within 2 weeks prior to first dose of study-drug treatment in Cycle 1 * Experimental therapy within 4 weeks prior to first dose of study-drug treatment in Cycle 1 * Major surgical procedure or significant traumatic injury within 4 weeks prior to the first dose of study-drug treatment in Cycle 1, or anticipation of the need for major surgery during the course of study treatment * Anti-cancer therapy within 28 days prior to the first dose of study-drug treatment in Cycle 1 * Current severe, uncontrolled systemic disease * History of clinically significant cardiac dysfunction * History of symptomatic congestive heart failure or serious cardiac arrhythmia requiring treatment * History of myocardial infarction within 6 months prior to the first dose of study-drug treatment in Cycle 1 * History of congenital long QT syndrome or QTc \> 470 msec * LVEF * History of malabsorption or other condition that would interfere with enteral absorption * Clinically significant history of liver disease, current alcohol abuse, or current known active infection with HIV, hepatitis B virus, or hepatitis C virus * Any condition requiring warfarin or thrombolytic anticoagulants * Active autoimmune disease * Uncontrolled ascites requiring weekly large volume paracentesis for 3 consecutive weeks prior to enrollment * Pregnancy, lactation, or breastfeeding * Known brain metastases that are untreated, symptomatic, or require therapy to control symptoms * No other history of or ongoing malignancy that would potentially interfere with the interpretation of the Pharmacodynamic (PD) or efficacy assays